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AMPP

:   American Migraine Prevalence and Prevention Study

AMS

:   American Migraine Study

CaMEO

:   Chronic Migraine Epidemiology and Outcomes Study

CM

:   chronic migraine

EM

:   episodic migraine

IBMS

:   International Burden of Migraine Study

ICHD

:   International Classification of Headache Disorders

MIDAS

:   Migraine Disability Assessment questionnaire

Many people with migraine do not consult clinicians or receive treatment with prescription drugs, and among those who do seek care, \<15% consult neurologists or headache specialists.[1](#head12878-bib-0001){ref-type="ref"}, [2](#head12878-bib-0002){ref-type="ref"} As a consequence, clinic‐based studies that rely on clinician diagnosis miss a substantial proportion of people with migraine and identify a sample with more severe disease and better access to medical care.[2](#head12878-bib-0002){ref-type="ref"} Therefore, studies that systematically ascertain disease‐state status in more representative non‐clinic samples are essential for increasing awareness and understanding of health conditions, such as migraine. Insights gained from these studies can document healthcare utilization and unmet diagnosis and treatment needs. Ultimately, these studies provide essential evidence for interventions designed to improve patient care and clinical outcomes.^3‐11^ [3](#head12878-bib-0003){ref-type="ref"}, [4](#head12878-bib-0004){ref-type="ref"}, [5](#head12878-bib-0005){ref-type="ref"}, [6](#head12878-bib-0006){ref-type="ref"}, [7](#head12878-bib-0007){ref-type="ref"}, [8](#head12878-bib-0008){ref-type="ref"}, [9](#head12878-bib-0009){ref-type="ref"}, [10](#head12878-bib-0010){ref-type="ref"}, [11](#head12878-bib-0011){ref-type="ref"}

The American Migraine Prevalence and Prevention (AMPP) Study,[12](#head12878-bib-0012){ref-type="ref"} conducted from 2004 to 2009, provided benchmark data for describing migraine prevalence, sociodemographic profiles, burden, comorbidity patterns, and prognosis. The AMPP Study also reported health‐related outcomes from the perspective of the person with migraine. The more recent Chronic Migraine Epidemiology and Outcomes (CaMEO) Study,[13](#head12878-bib-0013){ref-type="ref"} conducted from 2012 to 2013, expanded upon findings from the AMPP Study by providing a larger sample of persons with chronic migraine (CM), sampling headache frequency and disability every 3 months instead of annually, assessing impact of migraine on families from the perspective of different family members, and evaluating barriers to medical care for persons with migraine. Finally, the CaMEO Study sought to describe the relationship of migraine with underlying endophenotypes defined based on an expanded set of comorbidities and symptom profiles.

Differences in study methods, response rates, and sample sizes may raise questions about the representativeness of the CaMEO Study findings in comparison with findings from the more widely published AMPP Study. Because the AMPP Study had a much higher response rate (64.8% to the brief initial survey and 77.1% to the subsequent baseline longitudinal survey) and a large sample (162,576 respondents to the initial survey), data are more verifiably representative of the US migraine population. CaMEO had a lower response rate (16.5%), raising concerns about potential bias. We conducted this analysis to compare and contrast methodology and sample characteristics (sociodemographic, features, headache‐day frequency, headache‐related disability) in the AMPP and CaMEO studies. These results provide a context to better understand the results of the CaMEO Study.

METHODS {#head12878-sec-0007}
=======

Study Design {#head12878-sec-0008}
------------

Details of the methods used by the AMPP and CaMEO studies have been published previously^12‐14^ [12](#head12878-bib-0012){ref-type="ref"}, [13](#head12878-bib-0013){ref-type="ref"}, [14](#head12878-bib-0014){ref-type="ref"} and are contrasted in Table [1](#head12878-tbl-0001){ref-type="table-wrap"}. Briefly, the AMPP Study was based on the methods used in the American Migraine Study (AMS) and consisted of 2 phases; phase 1 began in 2004 and identified individuals with self‐reported severe headache in a stratified random sample of 120,000 households selected to be representative of the US population. Phase 2 began in 2005 and used mail surveys to determine headache features, treatment patterns, and comorbidities. The CaMEO Study was a web‐based study that used quota sampling to recruit a demographically representative sample of individuals in the United States. Cross‐sectional and longitudinal CaMEO Study modules were administered from September 2012 to November 2013. Both studies were approved by the institutional review board of the Albert Einstein College of Medicine.

###### 

Characteristics of the AMPP and CaMEO Studies

                                     AMPP                                                                                                             CaMEO
  ---------------------------------- ---------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Sample source                      Research panel of households                                                                                     Research panel of individuals
  Data collection method             Mailed questionnaire                                                                                             Web‐based survey
  Sampling method                    Demographically representative panel                                                                             Quota sampling from a demographically representative panel
  Study design                       Longitudinal study with cross‐sectional surveys                                                                  Longitudinal study with cross‐sectional surveys
  Baseline study year                2005                                                                                                             2012
  Duration                           Annually over 5 years                                                                                            Quarterly over 15 months
  Cases screened                     Severe headache                                                                                                  Headache
  Survey response rate, %            64.8/77.1[\*](#head12878-note-0003){ref-type="fn"}                                                               16.5
  Diagnostic criteria                Modified ICHD‐2[†](#head12878-note-0004){ref-type="fn"}                                                          Modified ICHD‐3 beta
  Diagnosis ascertained by           AMS/AMPP diagnostic module[15](#head12878-bib-0015){ref-type="ref"}, [16](#head12878-bib-0016){ref-type="ref"}   AMS/AMPP diagnostic module[15](#head12878-bib-0015){ref-type="ref"}, [16](#head12878-bib-0016){ref-type="ref"}
  Baseline migraine sample size, n   12,043                                                                                                           16,789
  CM, n (%)                          794 (6.6)                                                                                                        1,476 (8.8)
  EM, n (%)                          11,249 (93.4)                                                                                                    15,313 (91.2)
  Data focus                         Headache‐day frequency                                                                                           Headache‐day frequency
  Disability                         Disability                                                                                                       
  Healthcare utilization             Healthcare utilization                                                                                           
  Medication use                     Medication use                                                                                                   
  Diagnosis rates                    Treatment satisfaction                                                                                           
  Headache severity                  Barriers to medical care                                                                                         
  Allodynia                          Comorbidities                                                                                                    
  Lost productivity                  Quality of life                                                                                                  
  Comorbidities                      Family burden                                                                                                    

\*The response rate to the initial household screening study was 64.8%, and response to the baseline longitudinal study was 77.1%.

†Only ICHD‐2 symptom criteria were available in 2005; however, ICHD‐2 and ICHD‐3 beta are similar with respect to symptom criteria and case selection for migraine. Inclusion criteria are considered a modification of ICHD‐3 beta because 2 criteria were not confirmed: ≥5 lifetime migraine events (criterion A) and duration of attack untreated from 4--72 hours (criterion B).

AMPP, American Migraine Prevalence and Prevention; CaMEO, Chronic Migraine Epidemiology and Outcomes; CM, chronic migraine; EM, episodic migraine; ICHD, International Classification of Headache Disorders.

Study Population {#head12878-sec-0009}
----------------

The AMPP Study initially included adults and adolescents (age ≥12 years) with migraine and other headache types, and the CaMEO Study included only adults (age ≥18 years) with migraine. The present analysis includes only participants from both studies 18 years of age or older with migraine. We restricted the age of AMPP participants based on the age range in CaMEO. Both studies used the AMS/AMPP diagnostic module to assess the features of migraine.[15](#head12878-bib-0015){ref-type="ref"}, [16](#head12878-bib-0016){ref-type="ref"} The diagnostic criteria were a modification of the International Classification of Headache Disorders (ICHD) migraine criteria (ICHD‐2 for the AMPP Study, ICHD‐3b for the CaMEO Study).[17](#head12878-bib-0017){ref-type="ref"} Two criteria were not confirmed: ≥5 lifetime migraine events (criterion A) and duration of attack untreated from 4 to 72 hours (criterion B). In addition, alternative causes of headache were not excluded. CM classification was derived from Silberstein‐Lipton criteria[18](#head12878-bib-0018){ref-type="ref"}, [19](#head12878-bib-0019){ref-type="ref"} and ICHD‐3b criteria for CM. Respondents with CM were defined as those with ≥15 headache days per month averaged over the past 3 months but did not include assessment of ICHD‐3b CM criterion C (ie, ≥8 days per month fulfilled migraine criteria). This criterion was excluded because it is difficult to evaluate in a large, self‐report data‐collection paradigm and requires the use of a diary and physician interview to accurately diagnose. Although all CaMEO participants met diagnostic criteria for migraine, the AMPP Study also enrolled those with other severe headache. For comparability with the CaMEO Study, the AMPP Study data set was limited to migraine cases in this analysis.

Statistical Methods {#head12878-sec-0010}
-------------------

Baseline data from the AMPP (2005) and CaMEO (2012) studies were used in this analysis.[13](#head12878-bib-0013){ref-type="ref"}, [14](#head12878-bib-0014){ref-type="ref"} Between‐study comparative analyses captured the sociodemographic features of age, sex, income, and race. Comparison data were also generated for headache‐related disability and headache‐day frequency.

Headache‐related disability was assessed using the Migraine Disability Assessment (MIDAS) questionnaire, which categorized missed days of work, household chores, nonwork activity, and days with substantially reduced productivity (ie, \>50% reduction in productivity) in the same domains over a 3‐month period.[13](#head12878-bib-0013){ref-type="ref"}, [14](#head12878-bib-0014){ref-type="ref"} Scores were classified by severity as Grade I (little/no disability; score 0--5), Grade II (mild disability; score 6--10), Grade III (moderate disability; score 11--20), or Grade IV (severe disability; score ≥21).[20](#head12878-bib-0020){ref-type="ref"} MIDAS Grades III and IV were netted together and summarized for the purpose of this analysis. Headache‐day frequency was determined in both studies by asking respondents, "On how many days in the past 3 months (previous 90 days) did you have a headache?"[13](#head12878-bib-0013){ref-type="ref"}, [14](#head12878-bib-0014){ref-type="ref"} This number was then divided by 3 to estimate monthly headache‐day frequency.

Because MIDAS and headache‐day frequency are not normally distributed, median scores are presented as the measure of central tendency and interquartile range as the measure of dispersion for all comparisons. For this analysis, respondents from both studies were divided into episodic migraine (EM) and CM groups and further stratified by sex and age (18--29, 30--39, 40--49, 50--59, and ≥60 years). Descriptive statistics were generated to compare samples on key target measures. Statistical testing was not conducted because most of the between‐group comparisons involved very large samples. Large sample sizes increase the likelihood that statistical significance will be attributed to differences too small to be of clinical relevance.[21](#head12878-bib-0021){ref-type="ref"} All descriptive statistics were generated with SPSS Statistics, version 22.0 (IBM, Armonk, NY, USA).

RESULTS {#head12878-sec-0011}
=======

Study Design and Participants {#head12878-sec-0012}
-----------------------------

Key methodologic differences between the AMPP and CaMEO studies included the sampling unit (households vs individuals), method of data collection (mailed questionnaire vs web survey), and study duration (annually over 5 years vs quarterly over 15 months; Table [1](#head12878-tbl-0001){ref-type="table-wrap"}). Of the 120,000 households (representing 257,339 individuals) receiving the AMPP screening survey in 2004, 77,879 households (64.9% response rate) provided data, representing a total of 162,765 individuals aged ≥12 years.[22](#head12878-bib-0022){ref-type="ref"} Analysis of screening survey data identified 28,261 individuals who reported ≥1 severe headache in the past year. In 2005 (the baseline longitudinal year of phase 2 follow‐up), a longer postal survey was sent to 24,000 adults aged ≥18 years, 18,500 of whom returned valid surveys (77.1% response rate). Of these, 794 (6.6%) met criteria for CM and 11,249 (93.4%) met criteria for EM, for a total baseline sample of 12,043 respondents with migraine (Table [1](#head12878-tbl-0001){ref-type="table-wrap"}). For the CaMEO Study, 489,537 individuals were invited to participate in the study, and 80,783 (16.5%) responded with demographic and headache‐related screening information. Of the respondents, 58,418 provided complete and valid surveys, 16,789 of whom met diagnostic criteria for migraine (CM, n **=** 1,476 \[8.8%\]; EM, n **=** 15,313 \[91.2%\]; Table [1](#head12878-tbl-0001){ref-type="table-wrap"}).

Demographics {#head12878-sec-0013}
------------

Demographic distributions for age, sex, income, and race were generally similar between studies, indicating a broad US population representation for CM and EM (Table [2](#head12878-tbl-0002){ref-type="table-wrap"}). In comparison with the AMPP Study, the CaMEO Study had a higher proportion of young respondents (aged 18--29 years) and more people with higher incomes (≥\$50,000) for both CM and EM groups. Sample sizes were adequate to fairly represent all sex and age subgroups, except for the low number of men with CM from the AMPP Study (n **=** 163). Stratifying by age reduced the subset of men with CM from the AMPP Study to only 17 respondents in the 18‐ to 29‐year age group. Despite the small sample size, results for this segment were consistent between studies for all age subset comparisons.

###### 

Comparative Demographics for Baseline AMPP (2005) and Baseline CaMEO (2012) Studies Among Respondents With Episodic and Chronic Migraine

                       AMPP           CaMEO                                                                 
  -------------------- -------------- ----------------------------------------------------- --------------- --------------
  Age (years), n (%)                                                                                        
  18--29               1,337 (11.9)   88 (11.1)                                             4,267 (27.9)    364 (24.7)
  30--39               2,273 (20.2)   135 (17.0)                                            3,463 (22.6)    330 (22.4)
  40--49               3,101 (27.6)   217 (27.3)                                            3,126 (20.4)    350 (23.7)
  50--59               2,764 (24.6)   223 (28.1)                                            2,585 (16.9)    282 (19.1)
  \>60                 1,774 (15.8)   131 (16.5)                                            1,872 (12.2)    150 (10.2)
  Gender, n (%)                                                                                             
  Men                  2,254 (20.0)   163[\*](#head12878-note-0006){ref-type="fn"} (20.5)   4,015 (26.2)    279 (18.9)
  Women                8,995 (80.0)   631 (79.5)                                            11,298 (73.8)   1,197 (81.1)
  Race, n (%)                                                                                               
  White                9,827 (88.6)   720 (91.8)                                            12,752 (83.6)   1,292 (87.8)
  Non‐white            1,263 (11.4)   64 (8.2)                                              2,503 (16.4)    179 (12.2)
  Income, n (%)                                                                                             
  \<\$30,000           3,796 (33.7)   312 (39.3)                                            3,301 (21.7)    441 (30.2)
  \$30,000--\$49,999   2,424 (21.5)   168 (21.2)                                            2,694 (17.7)    296 (20.2)
  \$50,000--\$74,999   2,118 (18.8)   137 (17.3)                                            3,457 (22.7)    317 (21.7)
  \$≥75,000            2,911 (25.9)   177 (22.3)                                            5,750 (37.8)    408 (27.9)
  Median MIDAS score                                                                                        
  Men                  3              33                                                    4               32
  Women                6              45                                                    7               38

\*This N for AMPP Study men with CM is sufficiently large to provide reliable estimates for total sample comparisons but may not be reliable for comparisons stratified by age.

AMPP, American Migraine Prevalence and Prevention; CaMEO, Chronic Migraine Epidemiology and Outcomes; CM, chronic migraine; EM, episodic migraine; MIDAS, Migraine Disability Assessment.

Headache‐Related Disability {#head12878-sec-0014}
---------------------------

Median MIDAS score was substantially higher in both studies among those with CM (AMPP: men, score **=** 33; women, score **=** 45; CaMEO: men, score **=** 32; women, score **=** 38) than among those with EM (AMPP: men, score **=** 3; women, score **=** 6; CaMEO: men, score **=** 4; women, score **=** 7; Table [2](#head12878-tbl-0002){ref-type="table-wrap"}). In both studies, women experienced greater disability than men for CM and EM.

Rates of moderate to severe migraine‐related disability (MIDAS Grades III/IV) were similar for the AMPP and CaMEO studies (Fig. [1](#head12878-fig-0001){ref-type="fig"}). The percentage of respondents with Grade III/IV disability was higher in both studies for women compared with men for both CM and EM. In addition, rates of Grade III/IV disability were markedly higher in people with CM than EM, regardless of sex. The proportion of the CM and EM groups with Grade III/IV disability was higher in the CaMEO Study than in the AMPP Study, though differences were small.

![Baseline proportion of respondents with EM and CM with high disability (MIDAS Grade III/IV) in AMPP and CaMEO studies. AMPP, American Migraine Prevalence and Prevention; CaMEO, Chronic Migraine Epidemiology and Outcomes; MIDAS, Migraine Disability Assessment questionnaire.](HEAD-56-1280-g001){#head12878-fig-0001}

Headache‐Day Frequency {#head12878-sec-0015}
----------------------

Median headache‐day frequencies over the past month for respondents with CM and EM were similar in the AMPP and CaMEO studies (Fig. [2](#head12878-fig-0002){ref-type="fig"}). Median headache‐day frequencies were higher for respondents with CM than for those with EM, regardless of sex. Median headache‐day frequencies for respondents with EM ranged from 1.7 (men in the AMPP Study) to 3.0 (women in the CaMEO Study) headaches in the past month and were similar between studies.

![Baseline median headache‐day frequency for the past month for respondents with CM and EM in the AMPP and CaMEO studies. AMPP, American Migraine Prevalence and Prevention; CaMEO, Chronic Migraine Epidemiology and Outcomes.](HEAD-56-1280-g002){#head12878-fig-0002}

DISCUSSION {#head12878-sec-0016}
==========

The AMPP and CaMEO studies were longitudinal studies that included a broad base of respondents with migraine, representative of the US population. Comparison of baseline demographic data demonstrated similar age, sex, income, and race distributions among EM and CM subsamples between studies, with the exception of slightly higher incomes and a somewhat younger population in the CaMEO Study than in the AMPP Study. The overall distribution of headache‐related disability and headache‐day frequency was also similar between AMPP and CaMEO study respondents. Both studies demonstrated that migraine‐related disability was more severe in women than men and for those with CM than those with EM. Neither study showed sex differences in headache‐day frequency within the CM or EM cohorts. Of note, one sex‐ and age‐stratified CM subgroup from the AMPP Study (men aged 18--29 years) was small (n **=** 17) but resembled the CaMEO Study; however, because of the small sample size, these results should be interpreted with caution.

The most noteworthy methodological differences between the AMPP and CaMEO studies were methods of data collection, sampling strategy, and survey response rates. This analysis limited the age range of the AMPP Study sample ("severe headache," age ≥12 years) to that used in the CaMEO Study ("migraine," age ≥18 years). The differences in survey response rates (77.1% for the AMPP Study vs 16.5% for the CaMEO Study) are noteworthy because survey nonrespondents may differ from respondents in important ways, leading to biased study results.[23](#head12878-bib-0023){ref-type="ref"} To assess potential response bias in CaMEO, a follow‐up survey was sent to a random sample of CaMEO Study nonrespondents. A total of 88,451 individuals were sent study invitations and usable data were obtained from 8,225 (9.3% response rate). As expected for comparisons of large samples, some significant differences were observed in sample demographics between CaMEO respondents and nonrespondents, but the overall pattern of results and the positive case rates for migraine were comparable. However, the participation rate in the nonrespondent survey (9.3% of those invited) was too low to rule out response bias.[13](#head12878-bib-0013){ref-type="ref"}

The differences in baseline income and age distributions between AMPP and CaMEO studies may reflect differences in survey design because the CaMEO Study relied on internet access, a methodology more widely used in younger individuals and persons of higher socioeconomic status.[24](#head12878-bib-0024){ref-type="ref"}, [25](#head12878-bib-0025){ref-type="ref"} Persons with CM might have been underrepresented in the CaMEO Study, as CM occurs with higher prevalence in older, lower income, and lower education subgroups.[26](#head12878-bib-0026){ref-type="ref"} Additionally, lack of keyboard and internet literacy[27](#head12878-bib-0027){ref-type="ref"} may limit web‐based study participation for some people, including the elderly or those with learning or physical disabilities. However, among people with migraine, the relative frequency of CM was higher in the CaMEO Study (8.8%) than in the AMPP Study (6.6%), mitigating this cause. In addition, internet access continues to increase, especially among older people, minorities, and individuals with lower incomes or levels of educational achievement.[25](#head12878-bib-0025){ref-type="ref"} Despite potential drawbacks of internet‐based surveys, study designs are evolving, and use of web‐based surveys is expanding to include smartphones linked to the Internet. Smartphone use in the United States is widespread and growing,[28](#head12878-bib-0028){ref-type="ref"} and smartphone applications and text messaging are emerging as methods of conducting research[29](#head12878-bib-0029){ref-type="ref"}, [30](#head12878-bib-0030){ref-type="ref"} and may represent the next generation of epidemiologic surveys.

Both studies had some similar limitations. As is common in epidemiologic studies, all data were self‐reported, and were not verified by healthcare professionals or medical records. The AMPP Study included fewer males and young people, and the CaMEO Study had a low response rate, making the sample populations somewhat different.

These findings also compare favorably with published data from the cross‐sectional International Burden of Migraine Study (IBMS), a web‐based survey that collected data from 8,726 people with migraine in 9 countries.[31](#head12878-bib-0031){ref-type="ref"} In IBMS, the proportion of participants with CM was 5.7% and EM was 94.3%; demographic characteristics were also consistent with the AMPP and CaMEO studies, with the majority of respondents being female (CM, 85.6%; EM, 83.4%) and white (CM, 89.4%; EM, 85.9%). In addition, respondents with CM reported greater disability (mean MIDAS score: CM **=** 72.6, EM **=** 14.5) and higher rates of moderate/severe disability (MIDAS grade III/IV: CM **=** 89.6%, EM **=** 47.4%) than those with EM. Differences in the study populations may account for some of the variability in the results between IBMS and the AMPP and CaMEO studies, since both AMPP and CaMEO were US‐based and only 13.8% of the IBMS population was from the United States.

In sum, the CaMEO Study was conducted to complement and extend previous findings from the AMPP Study. Despite different survey methods and response rates, the overall consistency of findings between studies demonstrates that CaMEO Study respondents are as representative of people with migraine in the United States as AMPP respondents. The implications of these findings are important. The CaMEO Study has generated a wealth of data on persons with migraine that can be used to gain a better understanding of the burden of illness, naturally occurring comorbidity endophenotypes, and barriers to achieving adequate medical care for people with migraine, especially CM. CaMEO data have contributed important information regarding familial burden of migraine from the perspectives of the person with migraine, their partner, and child(ren), providing a more complete picture of migraine\'s impact on the family than any previous study.[32](#head12878-bib-0032){ref-type="ref"}, [33](#head12878-bib-0033){ref-type="ref"} In addition, the CaMEO Study provides novel information regarding naturally occurring comorbidity endophenotypes among people with migraine, including the contribution of noncephalic pain to new‐onset or persistent CM.[34](#head12878-bib-0034){ref-type="ref"} Although the AMPP Study explored barriers to adequate care for people with EM,[35](#head12878-bib-0035){ref-type="ref"} the CaMEO Study is the first to analyze and report on these barriers for those with CM.[2](#head12878-bib-0002){ref-type="ref"} Ultimately, the increased understanding of migraine garnered by CaMEO Study findings will help better identify individuals in need of care and inform improved disease management decisions for those who need it most.

CONCLUSIONS {#head12878-sec-0017}
===========

The AMPP and CaMEO studies were longitudinal cohort studies of people with migraine that used different methods but yielded similar results for the distribution of demographic characteristics, headache‐related disability, and headache‐day frequency. Comparability of outcomes between the AMPP and CaMEO studies implies that data generated from the CaMEO Study are generalizable to the US migraine population. Future analyses will compare studies for differences in headache consulting, diagnosis, and treatment patterns.
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